Alerts

Program of Targeting Microbiota 2024

Program ISM 2024

Join the International Society of Microbiota for its 11th World Congress on Targeting Microbiota, on October 14-15 at Corinthia Palace Malta!

Preliminary Program

Day 1 - Monday, October 14, 2024

Key note Speaker: 
The Kingdom of Microbiome: Where we are now and where we are heading?  Messages & Perspectives

Session 1:
Investigating the Role of Microbiota in Health & Disease: Mechanistic Insights and Recent Developments

Session 2:
Integrating One Health Approach: Environment, Animals and Human Lifestyle Factors in Health Strategy


Day 2 - Tuesday, October 15, 2024 

Session 3:
Advancements in Microbiome Medicine: A Multidisciplinary Perspective

   a. Fecal Microbiota Transplantation (FMT): Clinical Applications, Regulation and Insights

   b. Probiotics in Health & Disease Management: Strain-Specific Efficacy and Challenges

   c. Metabolites Analysis: Characterization and Synthetic Approaches for Clinical and Nutritional Research

   d. Phage Therapy: Emerging Applications and Challenges

   e. Extracellular Vesicles and Exosomes: Where is the Target?

Session 4: 

Workshop: Probiotic Prescribing Practices: Empowering Medical Doctors for Improved Patient Health

How Can We Integrate the Latest Research for Optimal Results?
What Are the Challenges and Opportunities in Current Probiotic Use?
How Can Next-Generation Probiotics Transform Patient Care?
How to select and provide the adequate probiotics to patients in 2024?

This specialized workshop will target medical professionals including cardiologists, neurologists, oncologists and others.

More information.

Targeting Microbiota 2024 Awards 


We are confident that the 11th Edition of Targeting Microbiota will be an exceptional meeting. We look forward to meeting you all in sunny Malta!

On behalf of the ISM Scientific Board

Workshop 2024: Probiotic Prescribing Practices: Empowering Medical Doctors for Improved Patient Health

ISM 2024 Workshop

The International Society of Microbiota is pleased to announce the organization of a new workshop on October 15, entitled:

"Probiotic Prescribing Practices: Empowering Medical Doctors for Improved Patient Health"

During the workshop, we will answer the following strategic questions:

1. How can we incorporate the latest research on the microbiome for the best outcomes?
2. What challenges and opportunities exist in the current use of probiotics?
3. In what ways can next-generation probiotics and metabolites revolutionize patient care?
4. How do we select and provide the right probiotics or metabolites to patients in 2024?
5. How can patient education on probiotics be improved for better self-management?
6. What role do probiotics play in personalized medicine and patient-specific treatments?
7. How can regulatory standards for probiotic products be enhanced to ensure quality and efficacy?
8. How to ensure marketing does not overshadow evidence-based probiotic benefits?
9. What is the optimal mode of probiotic administration: tablets, food, or fermented products?
10. What are the established safety limits for probiotic consumption?


Aim

The workshop's goal is to equip medical professionals with in-depth knowledge of the clinical applications of microbiota research, emphasizing the prescription of probiotics, the future potential of these treatments in health and disease.

Who Should Attend

- Medical Doctors and Practitioners
- Nutritionists
- Gynecologists
- Cardiologists
- Neurologists
- Oncologists
- Medical Researchers interested in microbiota
- Industry Representatives keen to share their innovations with the medical fraternity


Agenda Points:

Keynote Address:
State-of-the-art advancements in microbiota research across various medical domains.

Session on Probiotics in 2024:
Criteria for selecting appropriate probiotics for different health conditions.

Hot Topics:

1. How to Prescribe Probiotics?
- Guidelines for timing and duration of probiotic therapy.
- Case studies showcasing effective probiotic usage in clinical settings.
- Safety and efficacy considerations for specific probiotic strains.
- Clinical studies from industry

2. The Next Generation of Probiotics and Metabolites
- Innovations in probiotic formulations with strains and metabolites products.
- Potential clinical applications and implications for future research.

Closing Remarks:
- Recap of key learnings and insights.

Key Benefits for Attendees:
- Comprehensive update on microbiota research and clinical applications.
- Expert guidance on prescribing probiotics effectively.
- Insights into emerging trends in probiotics and metabolites for therapeutic use.


Invitation

We are particularly interested in showcasing innovative products, ingredients, and technologies related to probiotics. This is an excellent opportunity for your company to gain visibility, connect with healthcare professionals, and contribute to the advancement of probiotic application in medicine.

How to Participate

If your company is at the forefront of probiotic research and development and you wish to showcase your products or innovations, we warmly invite you to join us.

For participation details and to secure your slot in the agenda and space, please contact the ISM 2024 Workshop Organizing Committee directly. 

More Information on ISM 2024 Workshop


International Society of Microbiota
Press Releases | LinkedIn | Facebook

 Logo ISM2022 2048x931

Revolutionizing Depression Treatment: The Critical Role of Dietary Proline Exposed

fx1 lrg

A recent study has identified the microbiota-gut-brain axis as a promising area for the treatment of depression, which currently suffers from low efficacy rates. The research aimed to address current gaps in understanding, as most studies are underpowered and focus narrowly on major depression without considering the microbiome's functionality, composition, or external influences.

To tackle these challenges, the researchers utilized a multi-omics approach, integrating multiple types of biological data from pre-clinical models and three human cohorts with mild depression. The key findings revealed connections between depression and microbial metabolism affecting glutamate/GABA pathways, with a particular emphasis on the amino acid proline.

High dietary intake of proline emerged as the most significant dietary influence on depression. Furthermore, depression and high circulating proline levels were linked to disruptions in the brain's rich club network, which is responsible for integrating information from different brain regions.

In mice, proline supplementation led to worsened depressive symptoms and microbial translocation. Additionally, human microbiota transplantation in mice resulted in depressive behaviors and changes in genes related to GABA, proline, and the extracascular matrix in the prefrontal cortex.

Genetic and microbial interventions in Drosophila (fruit flies) offered further insights. Knockdown of proline and GABA transporters, along with mono-association with L. plantarum (a high GABA producer), provided protection against depressive states.

These findings suggest that targeting microbiome dynamics and dietary proline intake could lead to more effective depression treatments. The study highlights the importance of considering the complex interplay between the gut microbiota, diet, and brain function in the development and treatment of depression. Future research may build upon these findings to develop novel therapeutic strategies for depression and other mood disorders.

Stay updated on the latest advances on microbiome and depression during Targeting Microbiota 2024 this October. Submit a related abstract.

Read the full paper.

Copyright: International Society of Microbiota


International Society of Microbiota
LinkedIn | Facebook

Gut-Brain Connection: Key Insights into Neurodegenerative Diseases

The human gastrointestinal tract plays host to a rich ecosystem of microbes, collectively known as the gut microbiome. Recent advancements in sequencing technologies have deepened our understanding of the pivotal role this microbial community plays in human biology. From health maintenance to disease development, the gut microbiome's influence spans across various facets of human health.

41392 2024 1743 Fig1 HTML

The microbiota–gut–brain axis. The bidirectional communication between the gut microbiome and the brain is mediated by the immune system, vagus nerve, enteric nervous system, neuroendocrine system, and circulatory system. Alterations in gut microbiota have been linked to the development of autism spectrum disorders, anxiety, depressive-like behavior, impaired physical performance, and motivation, as well as neurodegenerative diseases. This figure was created with BioRender (https://biorender.com/). Credits: Jian Sheng Loh et al., 2024.

In a recent review published in the Signal Transduction and Targeted Therapy Journal, researchers delve into the intricate relationship between the gut microbiome and the central nervous system, termed the "microbiota-gut-brain axis". This bidirectional communication pathway has emerged as a crucial regulator of glial functions, offering promising avenues for mitigating the onset and progression of neurodegenerative diseases.

The review meticulously explores the mechanisms underlying the microbiota-gut-brain axis in neurodegenerative diseases. It elucidates how the gut microbiota communicates with key glial cells — microglia, astrocytes, and oligodendrocytes — during both healthy states and neurodegenerative conditions. Employing a metabolite-centric approach, the paper highlights the role of microbial metabolites, neurotransmitters, and gut hormones in modulating glial function and neurodegeneration.

Furthermore, the review investigates potential therapeutic targets along the microbiota-gut-brain axis, including the intestinal barrier, blood-brain barrier, meninges, and peripheral immune system. By addressing glial dysfunction at these interfaces, researchers aim to disrupt the pathological cascade associated with neurodegenerative diseases.

The paper wraps up by evaluating the preclinical and clinical evidence surrounding interventions targeting the gut microbiome, such as probiotics, prebiotics, and fecal microbiota transplantation, in the context of neurodegenerative diseases. A comprehensive understanding of the microbiota-gut-brain axis promises to catalyze the development of innovative therapeutic strategies for combating neurodegeneration, offering hope for millions affected by these debilitating conditions.

Targeting Microbiota 2024 will highlight the latest advancements in microbiota-gut-brain axis. Don't miss the chance to join the 11th ISM World Congress on October 14-15, 2024 at Corinthia Palace Malta!

Read the full paper.

Copyright: International Society of Microbiota


International Society of Microbiota
LinkedIn | Facebook

Fusobacterium nucleatum: A Key to Unlocking Colorectal Cancer Insights

Colorectal Cancer International Society of Microbiota

A recent review by researchers from California Institute of Behavioral Neurosciences & Psychology meticulously evaluates the influence of gut microbiota on the development and progression of colorectal cancer (CRC), a significant global health concern. Adhering to the PRISMA 2020 guidelines, a thorough database search was conducted, yielding 20 articles that met the inclusion criteria from 2000 to 2023.

Identifying Promising Microbiota Markers for Early Diagnosis and Treatment Enhancement

The review highlights the identification of specific microbiota markers, notably Fusobacterium nucleatum, which hold promise for early diagnosis and enhancing treatment of CRC. The synthesis of results underscores a significant correlation between gut and oral microbiota dysbiosis and CRC, suggesting that microbial markers could serve as cost-effective, noninvasive tools for early detection, monitoring recurrence, and evaluating treatment responses.

Addressing Challenges and Calling for Methodological Standardization

However, challenges such as establishing a cause-and-effect relationship, variability in study methodologies, and unaccounted variables like diet and lifestyle present limitations to the current understanding. The review calls for the standardization of microbiota research methodologies to allow for comparable findings across studies and suggests that future research should focus on large-scale multicenter longitudinal studies to validate specific biomarkers for developing universal diagnostic tools.

Exploring Novel Strategies for Prevention and Treatment

Additionally, exploring how microbiota influences CRC pathogenesis could lead to novel prevention and treatment strategies. Despite the low level of study overlap indicating a broad range of unique primary studies and reducing the risk of citation bias, the review acknowledges the need for a deeper understanding of the cause-and-effect relationship between gut microbiota and CRC.

In conclusion, leveraging microbiota markers for CRC could revolutionize early detection and monitoring, but further research is necessary to overcome current challenges and fully harness the potential of microbiome-centered treatments and preventive methods.

Targeting Microbiota 2024 will highlight the latest advancements in microbiome research and different diseases. Don't miss the chance to join the 11th ISM World Congress on October 14-15, 2024 at Corinthia Palace Malta!

Read the full paper.

Copyright: International Society of Microbiota

Image Credits: Freepik


International Society of Microbiota
LinkedIn | Facebook

Prof. Maria Cecilia Giron Appointed President of ISM, Pioneering Microbiota Research

GIRON

The scientific Board announce the appointment of Prof. Maria Cecilia Giron as the President of the International Society of Microbiota (ISM). This appointment marks a significant milestone in her illustrious career and promises to be a turning point in the field of microbiota research.

Dr. Giron has an extensive and impressive background in the field of pharmacology and clinical studies. Her invaluable contributions are evident through her roles in various prestigious committees, including the Ethics Committee for Clinical Studies at Padova University Hospital, the Ethics Committee for Oncological Clinical Trials at the Veneto Institute of Oncology, and the Veneto Region Medicines Evaluation Committee.

A true pioneer in her field, Dr. Giron's research has been instrumental in shedding light on the intricate relationship between gut microbiota and intestinal function in both normal and pathological conditions. Her dedication to advancing our understanding of microbiota's role in human health is underscored by her impressive portfolio of over 60 peer-reviewed publications.

Under her leadership, we anticipate that ISM will continue to flourish and lead the way in microbiota research, forging new paths and fostering collaboration to uncover the profound implications of microbiota in health and disease. We congratulate Prof. Maria Cecilia Giron on this remarkable achievement and eagerly await the exciting developments she will bring to the forefront of microbiota research.

Recognizing Prof. Lena Öhman's Outstanding Scientific Contribution to Microbiota Research at Targeting Microbiota 2023

Celebrating Prof. Lena Öhman’s Outstanding Scientific Contribution to Microbiota Research at Targeting Microbiota 2023

 Ohman  ISM Best scientific Contribution 1

We are delighted to celebrate the remarkable scientific contribution of Prof. Lena Öhman from the University of Gothenburg, Sweden, during Targeting Microbiota 2023.
She was awarded the ISM Scientific Contribution 2023.

Prof. Öhman, with a distinguished career spanning from her PhD thesis defense in 2002 to her recent appointment as a full professor in 2020, has made significant strides in the field of microbiota research.

A Pioneering Career

Prof. Öhman’s journey in academia has been nothing short of extraordinary. After completing her doctoral studies, she embarked on a journey that took her to Danone Research and INRAE Île-de-France - Jouy-en-Josas for a research sabbatical in 2012-2013. Her diverse experiences have enriched her perspective, leading to innovative insights in her field.

Unraveling Complexities in Gastrointestinal Disorders

During her captivating presentation at Targeting Microbiota 2023, Prof. Öhman delved deep into the intricate challenges posed by gastrointestinal disorders. Her talk not only explored the nuances of monitoring and diagnosing these diseases but also illuminated the mechanisms that underlie their initiation and persistence. Of particular significance was her examination of the potential of fecal gut microbiota and metabolite signatures as promising biomarkers for gastrointestinal disorders.

Dedicated Research Group

Prof. Öhman’s commitment to advancing our knowledge of gastrointestinal diseases extends beyond the lecture hall. She leads a dynamic research group at the University of Gothenburg, tirelessly working to uncover how gut microbiota and immune activity influence the course of these disorders. Their collective mission is to identify microbiotic and immunological indicators that can guide therapy decisions and improve outcomes for patients.

Prof, Öhman shared with the International Society of Microbiota: "We aim to continue to explore the potential of intestinal microbiota and metabolome as diagnostic biomarkers for inflammatory bowel disease, but also for colitis-associated colon cancer. Furthermore, we aim investigate the underlying principles of how commensal microbiota govern intestinal T cells and B cells in inflammatory bowel disease".

Innovative Approaches

In addition to discussing biomarkers, Prof. Öhman shared insights into the prospective use of in vitro cell culture models as powerful tools for studying the mechanisms of disease. Her comprehensive presentation illuminated the current state of research in this field, inspiring fellow researchers and clinicians alike.

We extend our heartfelt congratulations to Prof. Lena Öhman for her outstanding achievements and dedication to advancing our understanding of gastrointestinal disorders and the role of gut microbiota. Her pioneering contributions in the field are truly commendable, and we eagerly anticipate further advancements in this critical area of research.

Join Us in Celebrating Excellence

We invite you to join us in celebrating the excellence and dedication of Prof. Lena Öhman in the field of microbiota research. Her contributions have undoubtedly paved the way for a deeper understanding of gastrointestinal disorders and hold the promise of improved diagnostics and therapies in the future.

Stay tuned for more groundbreaking insights from leaders in microbiota research at Targeting Microbiota 2023.

Best Poster Award at Targeting Microbiota 2023 Spotlights Innovative Research

Best Poster 2023

Targeting Microbiota 2023 Best Poster Presentation Award

The International Society of Microbiota (ISM) is delighted to extend its warmest congratulations to Kelly Conde Pérez, from the Universitary Hospital of A Coruña, Spain, for her outstanding poster presentation titled:

Parvimonas Micra Translocates From Subgingival Pockets to Tumors in Colorectal Cancer Patients."

This remarkable poster presentation has illuminated a potential breakthrough in our understanding of the microbiota's role in colorectal cancer. Kelly's work suggested a fascinating link between the oral pathogen Parvimonas micra and tumors in colorectal cancer patients. The data presented indicated that P. micra not only coexists with other periodontal pathogens but also migrates to the gut, liver, and periodontal pockets. The efficiency of bacterial translocations appears to be enhanced when microorganisms form consortia.

Moreover, RNA-seq analysis provided compelling evidence that oral microbes exhibit increased activity within tumor tissues compared to healthy tissue. This groundbreaking research implies that Parvimonas micra, in conjunction with other pathobionts, may translocate from the oral cavity to the gut. This revelation opens up exciting possibilities, as P. micra could potentially serve as a non-invasive biomarker for colorectal cancer.

Kelly Conde Pérez's work embodies the spirit of innovative microbiota research, and her findings hold immense promise for advancing our understanding of colorectal cancer and its relationship with the microbiome.

The ISM commends Kelly for her exceptional contribution to the field and encourages young investigators to pursue their passion for microbiota research. We are committed to keeping you updated with the latest discoveries and advancements in this dynamic field. Stay engaged and stay tuned for more groundbreaking research!

Outstanding Presentation on Microbiota Manipulation for Cdkl5 Deficiency Disorder Receives Top Honors at Targeting Microbiota 2023

ISM 2023 Best Short Oral

Targeting Microbiota 2023 Best Short Oral Presentation Award

Francesca Damiani, from Scuola Normale Superiore, Italy, has been honored with the prestigious Best Short Oral Presentation award at Targeting Microbiota 2023. Her exceptional talk, titled "Microbiota Manipulation as a Potential Therapeutic Strategy to Improve Clinical Symptoms in CDKL5 Deficiency Disorder," stood out as a groundbreaking contribution to the field.

Cyclin-Dependent Kinase-Like 5 (CDKL5) deficiency disorder (CDD) is a rare X-linked developmental encephalopathy rooted in pathogenic variants of the CDKL5 gene. Beyond the array of neurological symptoms associated with CDD, patients frequently contend with gastrointestinal issues and underlying immune dysregulation as comorbidities. Dr. Damiani's research has shed light on the possible connection between these challenges and disturbances in the intestinal microbiota, specifically the presence of dysbiosis in CDD patients.

In her enlightening presentation, Dr. Damiani unveiled the promising clinical application of microbial manipulation as a non-invasive avenue to alleviate symptoms in individuals affected by CDD.

Dr. Damiani shared with the Internation Society of Microbiota (ISM) "Our research sheds light on the previously unexplored role of the gut microbiota-brain axis in influencing the behavioral and functional deficits observed in mouse models of CDD. In the future, we aim to elucidate the specific signals and pathways that mediate this connection, potentially offering innovative avenues for microbiota-based interventions in clinical practice. Moreover, to enhance the translational relevance of our findings, we plan to investigate the therapeutic potential of probiotic supplementation in CDD mice. In summary, targeting the intestinal microbiota could serve as a non-invasive alternative strategy to alleviate symptoms in CDD patients, and hopefully, in other neurodevelopmental disorders".

The International Society of Microbiota (ISM) extends its heartfelt congratulations to Dr. Damiani for her exceptional achievement. We eagerly anticipate learning more about her future research endeavors as she continues to make strides in the field of microbiota research.

Domestic Cleaning and Human Microbiome - Is There a Link?

Markus Egert updated 2023Prof. Markus Egert from Furtwangen University and active member of the ISM scientific committee, will chair a session on "Environment, Lifestyle & Microbiota: A "One Health" Approach" during Targeting Microbiota 2023.

 In industrialized countries, people spend up to 90% of their lifetime indoors. However, potential links between the indoor microbiome, the microbiome of daily used objects, the human microbiome and health and well-being are only poorly understood.

Prof. Egert will present a talk that will summarize current knowledge about how domestic cleaning and hygiene measures, predominantly aiming at the prevention of infectious diseases, might influence and shape the human microbiome and its effects on human health. His talk will conclude with suggestions on what "microbiome-friendly" household hygiene could look like. 

Prof. Egert's talk will be titled: "Domestic Cleaning and Human Microbiome - Is There a Link?"


About Prof. Egert

Markus Egert is professor for Microbiology and Hygiene at Furtwangen University of Applied Sciences (Black Forest, Germany). His work aims at a deeper understanding of the structural and functional interactions of microbial communities with humans.  He was one of the first researchers to apply the so-called RNA-based stable isotope probing technique (RNA-SIP) to intestinal ecosystem in order to identify prebiotics-degrading bacteria. In addition, he is known for his pioneering work on the microbiome of objects of daily use, such as kitchen sponges, spectacles and washing machines, and the hygienic relevance that goes with it.


Join Targeting Microbiota 2023 to learn more about Prof. Egert's talk. 

You can share your related work by submitting your abstract.

Targeting Microbiota 2023 Congress
October 17-19, 2023 - Venice
Linkedin | Facebook | Website

Mapping the Kitchen Microbiota in Five European Countries

Brigitte MoenDr. Birgitte Moen from Nofima—Norwegian Institute of Food, Fisheries and Aquaculture Research, Norway will join Targeting Microbiota 2023 on October 17-19 to present her latest research "Mapping the Kitchen Microbiota in Five European Countries".

Join Targeting Microbiota 2023 to learn more about Dr. Moen's talk. 

You can share your related work by submitting your abstract.

Targeting Microbiota 2023 Congress
October 17-19, 2023 - Venice
Linkedin | Facebook | Website

 

Gut microbiota and prebiotics in Parkinson's disease: The RESISTA-PD Trial

Andreas SchwiertzProf. Andreas Schwiertz, Institute of Microecology, Germany will present his latest research during Targeting Microbiota 2023 on October 17-19 in a talk titled "Gut microbiota and prebiotics in Parkinson's disease: The RESISTA-PD Trial".

The composition of the gut microbiome is linked to multiple diseases, including Parkinson’s disease (PD). Bacteria producing short-chain fatty acids (SCFAs) and fecal SCFA concentrations are reduced in PD. SCFAs exert various beneficial functions in humans. In the interventional, monocentric, open-label clinical trial RESISTA-PD Prof. Schwiertz and his colleagues aimed at altering fecal SCFAs by an 8-week prebiotic intervention with resistant starch (RS).

In the PD + RS group, fecal butyrate concentrations increased significantly, and fecal calprotectin concentrations dropped significantly.  Clinically, Prof. Schwiertz and his team observed a reduction in non-motor symptom load in the PD+RS group.


About Prof. Prof. Schwiertz

Dr. Andreas Schwiertz is a microbiologist and molecular biologist. He trained at the Carl von Ossietzky University, Oldenburg (GER), the University College Cork (IRL) and Sate University of St. Petersburg (RUS). He received his PhD from the University of Potsdam (GER), where he trained under Prof. Michael Blaut in human gastrointestinal microbiology and on probiotics. In 2012 he received his lecturer qualification from the Justus Liebig University of Giessen on gastrointestinal microbiology where he is associated professor. In 2003 he joined the Institute of Microecology in Herborn, where he serves currently as CEO and CSO.


Join Targeting Microbiota 2023 to learn more about Prof. Schwiertz's talk. You can learn more about Targeting Microbiota 2023 program here.

Targeting Microbiota 2023 Congress
October 17-19, 2023 - Venice
Linkedin | Facebook | Website

Microbiota, Enteric Nervous and Immune Systems: Barrier Defenses against Foodborne Pathogens Carriage in Poultry

Valentina Caputi Targeting Microbiota 2023Dr. Valentina Caputi, United States Department of Agriculture, Agricultural Research Service, USA, will join Targeting Microbiota 2023 on October 17-19 to present her latest research "Microbiota, Enteric Nervous and Immune Systems: Barrier Defenses against Foodborne Pathogens Carriage in Poultry".

The gastrointestinal tract is the largest body surface in contact with commensal microorganisms (or microbiota) and with pathogens, therefore the intestinal wall possesses a sophisticated system of barriers that protects the host from the translocation of pathogens, their molecular profiles, or environmental toxins in extra-intestinal tissues. The intestinal epithelium provides the first barrier defense against bacterial- or toxins translocation and its function is finely modulated by the immune system. Several studies have explored avian intestinal epithelial barrier alterations following Salmonella or Campylobacter infection. Submucosa and smooth muscle layers are located underneath the intestinal epithelium. These tissues are densely innervated by the enteric nervous system (ENS), a complex network of neurons and glial cells capable of functioning independently from the brain. The ENS is the principal coordinator of gut motility, peristalsis, nutrient absorption, and fluid secretion.

However, recent studies have shown that enteric neuronal populations are responsible for producing proinflammatory cytokines, thus stimulating the intestinal immune cells to release antimicrobial peptides against Salmonella infection in mammals. These results provide evidence of solid neuroimmune interactions in the gut that strengthen the canonical epithelial barrier against pathogenic infections such as Salmonella. The role of enteric neuroimmune interactions in chicken broilers affected by Salmonella or other foodborne pathogens has not been explored yet, and this research will provide a novel approach to understanding foodborne pathogens infection in poultry and ultimately formulate antibiotic alternatives aimed at preserving the integrity and function of the intestinal neuroimmune barriers. 

Join Targeting Microbiota 2023 to learn more about Dr. Caputi's talk. 

You can share your related work by submitting your abstract.

Targeting Microbiota 2023 Congress
October 17-19, 2023 - Venice
Linkedin | Facebook | Website

Skin Microbial Changes during Space Flights

Pamela Tozzo 1Dr. Pamela Tozzo from the University of Padova, Italy will join Targeting Microbiota 2023 on October 17-19 to present her latest research "Skin Microbial Changes during Space Flights".

Join Targeting Microbiota 2023 to learn more about Dr. Tozzo's talk. 

You can share your related work by submitting your abstract.

Targeting Microbiota 2023 Congress
October 17-19, 2023 - Venice
Linkedin | Facebook | Website

Microbiota & Myelinazation: The Latest Findings

Microbiota 2022 Congress speaker Maria Cecilia GironProf. Maria Cecilia Giron, local organizer of Targeting Microbiota 2023, University of Padova, Italy will join the conference and will give a presentation entitled "Microbiota & Myelinazation: The Latest Findings".

Join us in Targeting Microbiota 2023 and benefit from the experience of Prof. Giron. Don't forget that you can share your related work by submitting your abstract.

Targeting Microbiota 2023 Congress
October 17-19, 2023 - Venice
Linkedin | Facebook | Website

 

Microbiota, Prophages & Phage Therapy: The Missing Link

Marvin Edeas 4Prof. Marvin Edeas Founder & Chairman of ISM's Committee, Institut Cochin, INSERM, Université de Paris, France will join Targeting Microbiota 2023 on October 17-19 to present a talk entitled "Microbiota, Prophages & Phage Therapy: The Missing Link".

Join Targeting Microbiota 2023 to learn more about Prof. Edeas's talk. 

You can share your related work by submitting your abstract.

Targeting Microbiota 2023 Congress
October 17-19, 2023 - Venice
Linkedin | Facebook | Website

COVID 19 and Microbiota - A Story with a Long Tail

Prof Peter C. Konturek

Prof. Peter C. Konturek, President of ISM from  Teaching Hospital of the University of Jena, Germany will present a talk entitled "COVID 19 and Microbiota - A Story with a Long Tail".

Join Targeting Microbiota 2023 to learn more about Prof. Konturek's talk. 

You can share your related work by submitting your abstract.

Targeting Microbiota 2023 Congress
October 17-19, 2023 - Venice
Linkedin | Facebook | Website

Computational Modeling Microbial Community Networks: Pros and Cons

Barbara Di CamilloProf. Barbara Di Camillo, University of Padova, Italy will join Targeting Microbiota 2023 on October 17-19 to present her latest research "Computational Modeling Microbial Community Networks: Pros and Cons".

Join Targeting Microbiota 2023 to learn more about Prof. Di Camillo's talk. 

You can share your related work by submitting your abstract.

Targeting Microbiota 2023 Congress
October 17-19, 2023 - Venice
Linkedin | Facebook | Website

Marine Heatwaves and Microbiome in the Mediterranean Sea: Insights From Non Model Organism Manila Clam

Dr. Martino

Dr. Maria Elena Martino, University of Padova, Italy, will present her latest research during Targeting Microbiota 2023 on October 17-19 in a talk titled "Marine Heatwaves and Microbiome in the Mediterranean Sea:  Insights From Non Model Organism Manila Clam".

Extreme climatic events like Marine Heatwaves (MHWs) are becoming more intense and frequent and are severely threatening ecosystems’ health. Specifically, marine ecosystems are facing an increase in the prevalence of pathogenic microbes, causing significant shifts in the ecology and evolution of animal-microbiome symbiosis in marine environments. However, how extreme climate events shape the evolution and the adaptation of marine hosts and their microbiomes is still poorly understood.

Here, Dr. Martino and her team characterized the effect of heat waves on the microbiome of Manila clam Ruditapes philippinarum, one of the most widely farmed clam species worldwide, and investigated the ultimate effect on host health.


 You can learn more about Dr. Martino's talk this October in Venice.

Targeting Microbiota 2023 Congress
October 17-19, 2023 - Venice
Linkedin | Facebook | Website

Evaluation of Transitional Changes Shaping the Infants’ Gut Microbiota in Early Life: The CI.EMME Study

Prof. Di PilatoProf. Vincenzo Di Pilato from the University of Genoa, Italy will join Targeting Microbiota 2023 on October 17-19 to present his latest research "Evaluation of Transitional Changes Shaping the Infants' Gut Microbiota in Early Life: The CI.EMME Study".

The gut microbiota (GM) consists in a densely populated ecosystem that, from birth onwards, colonizes the intestinal tract through a highly dynamic processes, fundamental for health later in life. Indeed, disturbance of the GM in early life may results in lifelong consequences, and certain microbial features can be associated with disease states that are manifested at later stages, including asthma, inflammatory bowel disease, and metabolic disorders.

In the context of the CI.EMME study, Prof. Di Pilato and his team, longitudinally investigated the transitional changes of GM in a cohort of infants, expanding knowledge about the microbiota composition and maturation paths in early life.

Join Targeting Microbiota 2023 to learn more about Prof. Di Pilato's talk. 

You can share your related work by submitting your abstract.

Targeting Microbiota 2023 Congress
October 17-19, 2023 - Venice
Linkedin | Facebook | Website

Microbiome Engineering: Reprograming microbes to rewire host-microbiome interactions

Matthew ChangDr. Matthew Chang from the National University of Singapore, Singapore will join the Targeting Microbiota 2023 congress and will talk about "Microbiome Engineering: Reprograming microbes to rewire host-microbiome interactions".

The wealth of knowledge on the human microbiota composition and its roles in health and disease has recently spurred the development of novel therapeutic strategies. Moreover, with an array of genetic tools that are readily available, programmable genetic circuits can be designed, genomes can be edited and rewritten, and cells can be reprogrammed to foster novel microbiota-based interventions.

In this talk, Dr. Chang's recent work on engineering gut-resident microbes as versatile platforms equipped with clinically relevant functionalities will be presented. A particular emphasis will be placed on his team's efforts to transform gut microbes into live biotherapeutics with prophylactic and therapeutic efficacy against pathogenic infections and chronic metabolic diseases.

This work provides a strong foundation for engineering microbes to modulate host-microbiome interactions and supports the use of live biotherapeutics as a viable strategy for clinical intervention.


About Dr. Chang

Matthew Chang is Director of the National Centre for Engineering Biology, Singapore Consortium for Synthetic Biology, Wilmar-NUS Corporate Laboratory, and NUS Synthetic Biology for Clinical and Technological Innovation, and Dean’s Chair in Medicine and Associate Professor of Biochemistry and Synthetic Biology at the Yong Loo Lin School of Medicine at the National University of Singapore. His research focuses on studying the engineering of biology to develop autonomous, programmable cells for biomedical and biomanufacturing applications. He co-founded the Global Biofoundry Alliance and the Asian Synthetic Biology Association and serves as Co-Chair of the World Economic Forum’s Global Future Council on Synthetic Biology.


Join Targeting Microbiota 2023 to learn more about Dr. Chang's talk. 

You can share your related work by submitting your abstract.

Targeting Microbiota 2023 Congress
October 17-19, 2023 - Venice
Linkedin | Facebook | Website

Microbiota in the Press & Media

  • 1
  • 2
  • 3
Prev Next